Scholar Rock (NASDAQ:SRRK) posted its quarterly earnings results on Wednesday. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.07), Bloomberg Earnings reports. The company had revenue of $5.04 million for the quarter, compared to the consensus estimate of $5.38 million.

Scholar Rock stock traded down $0.69 during mid-day trading on Thursday, reaching $10.02. The company’s stock had a trading volume of 1,432 shares, compared to its average volume of 92,120. Scholar Rock has a 12-month low of $9.30 and a 12-month high of $30.00. The firm has a market cap of $267.77 million, a P/E ratio of -3.17 and a beta of -0.01. The company has a quick ratio of 4.76, a current ratio of 4.76 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average of $13.29.

A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of Scholar Rock from a “buy” rating to a “hold” rating in a report on Thursday, July 18th. Wedbush reiterated an “outperform” rating and issued a $27.00 price objective on shares of Scholar Rock in a research note on Wednesday, May 15th. Finally, ValuEngine upgraded shares of Scholar Rock from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.

Recommended Story: What is a price target?

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.